Literature DB >> 15145348

Recent advances in X-chromosome inactivation.

Edith Heard1.   

Abstract

X inactivation is the silencing one of the two X chromosomes in XX female mammals. Initiation of this process during early development is controlled by the X-inactivation centre, a complex locus that determines how many, and which, X chromosomes will be inactivated. It also produces the Xist transcript, a remarkable RNA that coats the X chromosome in cis and triggers its silencing. Xist RNA coating induces a cascade of chromatin changes on the X chromosome, including the recruitment of Polycomb group proteins. This results in an inactive state that is initially labile, but may be further locked in by epigenetic marks such as DNA methylation. In mice, X inactivation has recently been found to be much more dynamic than previously thought during early pre-implantation development. The paternal X chromosome is initially inactivated in all cells of cleavage-stage embryos and then selectively reactivated in the subset of cells that will form the embryo, with random X inactivation occurring thereafter.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145348     DOI: 10.1016/j.ceb.2004.03.005

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  89 in total

1.  Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus.

Authors:  Faith M Strickland; Anura Hewagama; Qianjian Lu; Ailing Wu; Robert Hinderer; Ryan Webb; Kent Johnson; Amr H Sawalha; Colin Delaney; Raymond Yung; Bruce C Richardson
Journal:  J Autoimmun       Date:  2011-12-03       Impact factor: 7.094

2.  Epigenetics of heterochromatin.

Authors:  Subhash C Lakhotia
Journal:  J Biosci       Date:  2004-09       Impact factor: 1.826

Review 3.  Architectural epigenetics: mitotic retention of mammalian transcriptional regulatory information.

Authors:  Sayyed K Zaidi; Daniel W Young; Martin Montecino; Jane B Lian; Janet L Stein; Andre J van Wijnen; Gary S Stein
Journal:  Mol Cell Biol       Date:  2010-08-09       Impact factor: 4.272

4.  Epigenetic modifications on X chromosomes in marsupial and monotreme mammals and implications for evolution of dosage compensation.

Authors:  Willem Rens; Margaret S Wallduck; Frances L Lovell; Malcolm A Ferguson-Smith; Anne C Ferguson-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-22       Impact factor: 11.205

5.  Histone lysine methylation patterns in human cell types are arranged in distinct three-dimensional nuclear zones.

Authors:  Roman Zinner; Heiner Albiez; Joachim Walter; Antoine H F M Peters; Thomas Cremer; Marion Cremer
Journal:  Histochem Cell Biol       Date:  2005-10-08       Impact factor: 4.304

6.  Heterochromatin formation involves changes in histone modifications over multiple cell generations.

Authors:  Yael Katan-Khaykovich; Kevin Struhl
Journal:  EMBO J       Date:  2005-05-26       Impact factor: 11.598

7.  Initiation of epigenetic reprogramming of the X chromosome in somatic nuclei transplanted to a mouse oocyte.

Authors:  Siqin Bao; Naoki Miyoshi; Ikuhiro Okamoto; Thomas Jenuwein; Edith Heard; M Azim Surani
Journal:  EMBO Rep       Date:  2005-08       Impact factor: 8.807

8.  Multiple spatially distinct types of facultative heterochromatin on the human inactive X chromosome.

Authors:  Brian P Chadwick; Huntington F Willard
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

9.  The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.

Authors:  Sivaprakasam Balasubramanian; Gautam Adhikary; Richard L Eckert
Journal:  Carcinogenesis       Date:  2009-12-16       Impact factor: 4.944

10.  Non-imprinted allele-specific DNA methylation on human autosomes.

Authors:  Yingying Zhang; Christian Rohde; Richard Reinhardt; Claudia Voelcker-Rehage; Albert Jeltsch
Journal:  Genome Biol       Date:  2009-12-03       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.